Disease-Modifying ASO Therapy for Mitchell Syndrome and Obesity

by | Jun 1, 2026 | Bucelli, Robert, Hubler, Zita, Miller, Timothy, Schoch, Kathleen

— Published date: 6/2/2026

Value Proposition: First-in-class antisense oligonucleotide (ASO) therapy selectively lowering ACOX1 to enable disease-modifying treatment of Mitchell Syndrome and unlocking a metabolic shift facilitating weight loss.

Technology Description: Mitchell Syndrome is an u…